This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hamilton, S. R. Articles by Golightly, S. Search for Related Content PubMed PubMed Citation Articles by Hamilton, S. R. Articles by Golightly, S.

Evaluation of Dietary Dehydroepiandrosterone for Chemoprotection against Tumorigenesis in Premalignant Colonic Epithelium of Male F344 Rats¹

Department of Pathology [S. R. H., J. F., S. G.] and Oncology Center [S. R. H., G. B. G.], The Johns Hopkins University School of Medicine and Hospital, Baltimore, Maryland 21205

Epidemiological and experimental studies suggest that dehydroepiandrosterone (DHEA), an adrenal cortical steroid, has chemoprotective properties. Rat colonic epithelium which had been induced to a premalignant state by the colonic carcinogen azoxymethane was used as a model for patients at high risk of colorectal carcinoma, and the efficacy of dietary DHEA for chemoprotection against tumorigenesis was evaluated. Ten-week-old male F344 rats (n = 100) were given 10 weekly s.c. injections of azoxymethane at a dose of 10 mg/kg/week. One day after the final dose of carcinogen, DHEA was added to the diet of 50 rats (0.5% DHEA chow), and the other rats were used as pair-fed controls. DHEA-fed rats lost body weight throughout the 17-week study, in contrast to their pair-fed controls. Serum DHEA in DHEA-fed rats at the end of the study was 6 times that of controls (120 ± 30 versus 18 ± 14 pmol/ml), and serum DHEA sulfate was 23 times that of controls (1311 ± 13 versus 55 ± 13 pmol/ml). Addition of DHEA to the diet produced no significant chemoprotection in our model. Tumor-related mortality was somewhat increased in DHEA-fed rats (20% versus 6% in week 16 of DHEA feeding, P not significant). The cumulative prevalence of left colonic tumors, identified by weekly colonoscopic examinations, was somewhat lower in DHEA-fed rats than in controls during weeks 10 through 13 (17% versus 33% in week 12, P not significant), but in week 14 the prevalence in DHEA-fed rats became similar to that in controls (39% versus 41%). Growth curves of autochthonous left colonic tumors, as assessed for 8 weeks by computerized image analysis of colonoscopic photographs, were similar for DHEA-fed and control rats. Prevalence, mean frequency, multiplicity, and diameter of colonic tumors at necropsy of colonoscopically negative rats in week 17 were somewhat lower in the DHEA-fed rats (e.g., prevalence of 47% versus 67%), but the differences from controls were not significant. Parameters of colonic epithelial proliferation after tritiated thymidine incorporation in DHEA-fed rats were similar to those in control rats (labeling index of 8.3 ± 0.7% versus 8.4 ± 0.6% in week 17), despite higher serum DHEA and DHEA sulfate levels. Our findings indicate that DHEA did not have significant postinduction chemoprotective activity against azoxymethane-induced colonic tumorigenesis in this model utilizing pair-fed controls. Further preclinical studies appear to be needed before dietary DHEA can be recommended for chemoprotection trials in patients with premalignant colorectal epithelium.

¹ This study was supported by the Clayton Fund, the McAshan Fund, and Grant PO1 CA44530 from the National Cancer Institute, NIH, Department of Health and Human Services. S. R. H. is a recipient of a Young Faculty Award from E. I. Du Pont de Nemours & Co. G. B. G. is a recipient of a Keck Foundation Clinician Scientist Award from The Johns Hopkins Medical Institutions. This study was presented in part at the 1988 annual meeting of the American Association for Cancer Research (57).

² To whom requests for reprints should be addressed, at Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD 21205.

Received 7/ 9/90. Accepted 10/29/90.

This article has been cited by other articles:

				A. J. Alberg, G. B. Gordon, S. C. Hoffman, G. W. Comstock, and K. J. Helzlsouer Serum Dehydroepiandrosterone and Dehydroepiandrosterone Sulfate and the Subsequent Risk of Developing Colon Cancer Cancer Epidemiol. Biomarkers Prev., May 1, 2000; 9(5): 517 - 521. [Abstract] [Full Text]